AAAAAA
Results:
1-21
|
Results: 21
Authors:
Aviezer, D
Seddon, AP
Wildey, MJ
Bohlen, P
Yayon, A
Citation: D. Aviezer et al., Development of a high throughput screening assay for inhibitors of fibroblast growth factor-receptor-heparin interactions, J BIOMOL SC, 6(3), 2001, pp. 171-177
Authors:
Landau, Z
David, M
Aviezer, D
Yayon, A
Citation: Z. Landau et al., Heparin-like inhibitory activity to fibroblast growth factor-2 in wound fluids of patients with chronic skin ulcers and its modulation during wound healing, WOUND R REG, 9(4), 2001, pp. 323-328
Authors:
Boldicke, T
Tesar, M
Griesel, C
Rohde, M
Grone, HJ
Waltenberger, J
Kollet, G
Lapidot, T
Yayon, A
Weich, H
Citation: T. Boldicke et al., Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizingthe human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) onthe surface of primary endothelial cells and preselected. CD34(+) cells from cord blood, STEM CELLS, 19(1), 2001, pp. 24-36
Authors:
Hecht, HJ
Adar, R
Hofmann, B
Bogin, O
Weich, H
Yayon, A
Citation: Hj. Hecht et al., Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor- and heparin-binding interfaces, ACT CRYST D, 57, 2001, pp. 378-384
Authors:
Robinson, D
Hasharoni, A
Oganesian, A
Sandell, LJ
Yayon, A
Nevo, Z
Citation: D. Robinson et al., Role of FGF9 and FGF receptor 3 in osteochondroma formation, ORTHOPEDICS, 24(8), 2001, pp. 783-787
Authors:
Kruchkova, Y
Ben-Dror, I
Herschkovitz, A
David, M
Yayon, A
Vardimon, L
Citation: Y. Kruchkova et al., Basic fibroblast growth factor: a potential inhibitor of glutamine synthetase expression in injured neural tissue, J NEUROCHEM, 77(6), 2001, pp. 1641-1649
Authors:
Zvibel, I
Brill, S
Halpern, Z
Moskovitz, S
Yayon, A
Papa, M
Citation: I. Zvibel et al., Soluble and matrix-associated heparan sulfate proteoglycans increase expression of erb-B2 and erb-B3 in colon cancer cell lines, INT J CANC, 91(3), 2001, pp. 316-321
Authors:
Adar, R
Yayon, A
Citation: R. Adar et A. Yayon, Mapping a heparin binding site on ErbB-3 epidermal growth factor receptor, BIOC BIOP R, 283(1), 2001, pp. 1-5
Authors:
Schlessinger, J
Plotnikov, AN
Ibrahimi, OA
Eliseenkova, AV
Yeh, BK
Yayon, A
Linhardt, RJ
Mohammadi, M
Citation: J. Schlessinger et al., Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization, MOL CELL, 6(3), 2000, pp. 743-750
Authors:
Segev, O
Chumakov, I
Nevo, Z
Givol, D
Madar-Shapiro, L
Sheinin, Y
Weinreb, M
Yayon, A
Citation: O. Segev et al., Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice, HUM MOL GEN, 9(2), 2000, pp. 249-258
Authors:
Monsonego-Ornan, E
Adar, R
Feferman, T
Segev, O
Yayon, A
Citation: E. Monsonego-ornan et al., The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation, MOL CELL B, 20(2), 2000, pp. 516-522
Oligomerization reduces heparin affinity but enhances receptor binding of fibroblast growth factor 2
Authors:
Safran, M
Eisenstein, M
Aviezer, D
Yayon, A
Citation: M. Safran et al., Oligomerization reduces heparin affinity but enhances receptor binding of fibroblast growth factor 2, BIOCHEM J, 345, 2000, pp. 107-113
Authors:
Moshitch-Moshkovitz, S
Heldman, Y
Yayon, A
Katchalski-Katzir, E
Citation: S. Moshitch-moshkovitz et al., Sorting polyclonal antibodies into functionally distinct fractions using peptide phage display: 'a library on top of a library', J IMMUNOL M, 242(1-2), 2000, pp. 183-191
Authors:
Aviezer, D
Cotton, S
David, M
Segev, A
Khaselev, N
Galili, N
Gross, Z
Yayon, A
Citation: D. Aviezer et al., Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelialcell proliferation, tumor progression, and metastasis, CANCER RES, 60(11), 2000, pp. 2973-2980
Authors:
Robinson, D
Hasharoni, A
Halperin, N
Yayon, A
Nevo, Z
Citation: D. Robinson et al., Mesenchymal cells and growth factors in bunions, FOOT ANKL I, 20(11), 1999, pp. 727-732
Authors:
Garofalo, S
Kliger-Spatz, M
Cooke, JL
Wolstin, O
Lunstrum, GP
Moshkovitz, SM
Horton, WA
Yayon, A
Citation: S. Garofalo et al., Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice, J BONE MIN, 14(11), 1999, pp. 1909-1915
Authors:
Wang, YC
Spatz, MK
Kannan, K
Hayk, H
Avivi, A
Gorivodsky, M
Pines, M
Yayon, A
Lonai, P
Givol, D
Citation: Yc. Wang et al., A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3, P NAS US, 96(8), 1999, pp. 4455-4460
Authors:
Hornig, C
Behn, T
Bartsch, W
Yayon, A
Weich, HA
Citation: C. Hornig et al., Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA, J IMMUNOL M, 226(1-2), 1999, pp. 169-177
Authors:
Chen, L
Adar, R
Yang, X
Monsonego, EO
Li, CL
Hauschka, PV
Yayon, A
Deng, CX
Citation: L. Chen et al., Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis, J CLIN INV, 104(11), 1999, pp. 1517-1525
Authors:
Robinson, D
Hasharoni, A
Cohen, N
Yayon, A
Moskowitz, RM
Nevo, Z
Citation: D. Robinson et al., Fibroblast growth factor receptor-3 as a marker for precartilaginous stem cells, CLIN ORTHOP, (367), 1999, pp. S163-S175
Authors:
Aviezer, D
Safran, M
Yayon, A
Citation: D. Aviezer et al., Heparin differentially regulates the interaction of fibroblast growth factor-4 with FGF receptors 1 and 2, BIOC BIOP R, 263(3), 1999, pp. 621-626
Risultati:
1-21
|